Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain

Spain Aisling, Howarth Clare, Khrapitchev Alexandre A., Sharp Trevor, Sibson Nicola R., Martin Chris

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (65)

  1. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. 2015-01-15 · Expand citations
  2. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. 2012-03-01 · Expand citations
  3. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. 2012-02-07 · Expand citations
  4. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. 2012-02-01 · Expand citations
  5. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. 2011-09-01 · Expand citations
  6. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. 2011-01-01 · Expand citations
  7. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. 2010-09-01 · Expand citations
  8. The pharmacology of psilocybin. 2002-10-01 · Expand citations
  9. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. 1999-06-01 · Expand citations
  10. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. 1998-12-01 · Expand citations
  11. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
  12. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. 1997-05-01 · Expand citations
  13. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. 1966-12-30 · Expand citations
  14. 10.1002/jmri.20584
  15. 10.1002/jmri.23914
  16. 10.1002/nbm.1940070106
  17. 10.1007/bf01062336
  18. 10.1007/s00213-014-3855-0
  19. 10.1007/s12035-011-8214-0
  20. 10.1016/0163-7258(94)90048-5
  21. 10.1016/j.dcn.2013.07.003
  22. 10.1016/j.ejphar.2012.05.031
  23. 10.1016/j.neubiorev.2013.07.018
  24. 10.1016/j.neuroimage.2004.08.011
  25. 10.1016/j.neuroimage.2004.12.010
  26. 10.1016/j.neuroimage.2005.08.028
  27. 10.1016/j.neuroimage.2006.02.021
  28. 10.1016/j.neuroimage.2006.11.010
  29. 10.1016/j.neuroimage.2009.06.021
  30. 10.1016/j.neuroimage.2009.10.013
  31. 10.1016/j.neuroimage.2010.03.060
  32. 10.1016/j.neuroimage.2011.09.015
  33. 10.1016/j.neuroimage.2012.01.040
  34. 10.1016/j.neuroimage.2012.10.006
  35. 10.1016/j.neuroimage.2013.02.046
  36. 10.1016/j.neuroimage.2013.03.002
  37. 10.1016/j.neuron.2007.11.008
  38. 10.1016/j.neuropharm.2008.08.014
  39. 10.1016/j.neuropharm.2011.01.015
  40. 10.1016/j.neuroscience.2009.10.006
  41. 10.1016/j.pharmthera.2010.06.005
  42. 10.1016/s0006-8993(01)03121-3
  43. 10.1016/s0165-0270(03)00192-4
  44. 10.1016/s0301-0082(96)00033-0
  45. 10.1017/s1461145714000261
  46. 10.1038/jcbfm.1992.127
  47. 10.1038/jcbfm.2012.23
  48. 10.1038/nature06976
  49. 10.1038/nn1675
  50. 10.1038/nrd2027
  51. 10.1046/j.1468-2982.2002.00395.x
  52. 10.1073/pnas.0407789102
  53. 10.1093/schbul/sbt086
  54. 10.1097/00004647-200208000-00002
  55. 10.1111/ejn.12024
  56. 10.1111/j.1460-9568.2009.06812.x
  57. 10.1126/science.1110948
  58. 10.1152/japplphysiol.00954.2005
  59. 10.1177/0269881110372547
  60. 10.1371/journal.pone.0009019
  61. 10.1523/jneurosci.3065-04.2004
  62. 10.1523/jneurosci.3346-12.2013
  63. 10.1523/jneurosci.3447-08.2009
  64. 10.1523/jneurosci.5015-08.2009
  65. 10.1523/jneurosci.6063-09.2010

Cited by — these papers cite this paper (2)

  1. Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors 2026-03-26 · Expand citations
  2. Acute psilocin increased cortical activity in rat 2026-02-04 · Expand citations